Integra Lifesciences Holdings Corp (NASDAQ:IART) reaffirmed FY22 revenue guidance at the midpoint of its August 2022 guidance of $1.551 billion – $1.563 billion with an estimate of $1.57 billion. It raised FY22 adj EPS outlook to $3.29 – $3.33 versus an estimate of $3.24.
Valneva Has Completed Enrollment And Vaccination For A Phase 3 VLA 1553-321 Trial In Adolescents Of Its Single-shot Chikungunya Vaccine Candidate, VLA 1553
The first results are expected in mid 2023.
